PRG 2302
Alternative Names: PRG-2302Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator Pregene ShenZhen Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2024 Pregene ShenZhen Biotechnology plans a clinical trial for B-cell-lymphoma (Second-line therapy or greater, Recurrent) in China in October 2024 (Parenteral) (ChiCTR2400091403)
- 24 May 2024 Phase-0 for Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, Recurrent) in China (Parenteral) (NCT06659653)